

Standard Dose Influenza Vaccines Trivalent Inactivated

BIOLOGICAL PAGE

Section 7	Biological Product Information	Standard # 07.265
Created and approved by	Provincial Immunization Program	
Approval date	September 4, 2015	Published September 23, 2026

	FLUCELVAX	Fluviral	Fluzone
Manufacturer	Seqirus UK Limited	GlaxoSmithKline Inc.	Sanofi Pasteur Inc.
Classification	Trivalent, inactivated subunit vaccine	Trivalent, inactivated split virion vaccine	
Indications for Provincially Funded Vaccine	Individuals 6 months of age and older. If available, the following are recommended: - High dose inactivated influenza vaccine is recommended for adults 18 years of age and older who are: - Hematopoietic stem cell transplant (HSCT) recipients - CAR T-cell therapy recipients; or - Solid organ transplant (SOT) candidates or recipients - Adjuvanted inactivated vaccine is recommended for adults 65 years of age and older. Note: - Persons who live, work, go to school or are visiting in Alberta are eligible to receive provincially funded influenza vaccine.		
Influenza Strains for 2025-2026 Season	Cell-Cultured A/Missouri/11/2025 (H1N1)pdm09-like virus A/Darwin/1415/2025 (H3N2)-like virus B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus	Egg-Based A/Missouri/11/2025 (H1N1)pdm09-like virus A/Darwin/1454/2025 (H3N2)-like virus B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus	
Dose	0.5 mL		
Route	I.M.		
Schedule	6 months up to and including 8 years of age who have not received influenza vaccine in a previous season: 2 doses with a minimum interval of 4 weeks between doses 6 months up to and including 8 years of age who have received influenza vaccine in a previous season: 1 dose 9 years of age and older: 1 dose		

	FLUCELVAX	Fluviral	Fluzone
	Note: For HSCT, SOT and/or CAR-T cell therapy recipients see: Principles of Immunization for Hematopoietic Stem Cell Transplant and Solid Organ Transplant Recipients Immunization for Adult HSCT Transplant Recipients Immunization for Child HSCT Transplant Recipients Immunization of Adult Solid Organ Transplant (SOT) Candidates and Recipients Immunization of Children Expecting Solid Organ Transplant Before 18 Months of Age (Accelerated) Immunization for Children Expecting Solid Organ Transplant After 18 Months of Age (Catch-up and Ongoing Schedule)		
Contraindications/ Precautions	Contraindications: • Infants less than 6 months of age. • Known hypersensitivity to any component of the vaccine excluding eggs. • Anaphylactic or other allergic reactions to a previous dose of influenza vaccine. • Known history of Guillain Barré Syndrome (GBS) within 6 weeks of a previous dose of influenza vaccine, unless another cause was found for the GBS. ○ The potential risk of GBS recurrence associated with influenza vaccine must be balanced against the risk of GBS associated with influenza infection itself and the other benefits of influenza immunization. The relative and attributable risks of GBS after seasonal influenza immunization are lower than those after influenza illness. Precautions: • Egg allergy is not considered a contraindication for inactivated influenza vaccine. • Egg allergic individuals may be safely immunized using inactivated influenza vaccine without a prior influenza vaccine skin test and with the full dose of vaccine even if they have a past severe reaction to egg. They can be immunized in any setting. Keep them under observation for 30 minutes following the administration of inactivated influenza vaccine. • Consult with the Medical Officer of Health to review the risks and benefits of further influenza immunization for individuals with a history of oculorespiratory syndrome (ORS) that included lower respiratory symptoms (wheeze, chest tightness, difficulty breathing) within 24 hours of receiving influenza vaccine		
Possible Reactions	Common: • Pain, redness, bruising, induration and swelling at the injection site • Fever, chills • Cough, chest tightness, runny nose, sore throat, red eyes • Fatigue, drowsiness, malaise • Irritability, crying • Headache, arthralgia, myalgia • Loss of appetite • Gastrointestinal symptoms (nausea, vomiting, diarrhea) Uncommon: • Hematoma, warmth, rash at injection site • Upper abdominal pain • Rash (general) • Sweating Rare: • Anaphylaxis, allergic reaction • Guillain-Barré Syndrome (GBS)		

	FLUCELVAX	Fluviral	Fluzone
	• ORS is defined by the following symptoms occurring within 24 hours of immunization: ○ bilateral red eyes and ○ one or more of the following respiratory symptoms (cough, wheeze, chest tightness, difficulty breathing, difficulty swallowing, hoarseness, sore throat) with or without facial swelling. ○ Individuals who have an occurrence or recurrence of ORS upon immunization do not necessarily experience further episodes with future immunizations. • Unexpected or unusual side effects can occur. Refer to product monograph for more detailed information.		
Pregnancy	May use during pregnancy. • Inactivated influenza immunization is recommended at any stage of pregnancy due to the risk of influenza morbidity. • The safety of inactivated influenza vaccine during pregnancy has been reviewed and has not shown evidence of harm to the pregnant individual or fetus.		
Lactation	No contraindication.		
Composition	Each 0.5 mL dose contains: • 15 mcg influenza virus haemagglutinin (HA) from each of the three virus strains • disodium phosphate dihydrate • magnesium chloride hexahydrate • potassium chloride • potassium dihydrogen phosphate • sodium chloride • water for injection Trace residual amounts of: • beta-propiolactone • cetyltrimethylammonium bromide • polysorbate 80 *Thimerosal is present in the multi-dose product only Propagated in Madin Darby Canine Kidney (MDCK) cells	Each 0.5 mL dose contains: • 15 mcg influenza virus haemagglutinin (HA) surface antigen from each of the three virus strains • egg proteins • ethanol • formaldehyde • phosphate buffered saline • polysorbate 80 • sodium deoxycholate • α-tocopheryl hydrogen succinate • sucrose *Thimerosal is present in the multi-dose product only Prepared from virus grown in the allantoic cavity of embryonated hens' eggs	Each 0.5 mL dose contains: • 15 mcg influenza virus haemagglutinin (HA) from each of the three virus strains • phosphate buffered saline • water for injection • Triton X-100 NMT *Thimerosal is present in the multidose product only Propagated in embryonated chicken eggs
Blood/Blood Products	Does not contain human blood/blood products.		
Bovine/Porcine Products	Does not contain bovine or porcine products.		
Latex	Does not contain latex.		
Interchangeability	For children requiring a second dose of influenza vaccine, either inactivated or live attenuated influenza vaccines can be used interchangeably. Ensure a minimum interval of 4 weeks between doses.		

	FLUCELVAX	Fluviral	Fluzone
Administration with Other Products	Influenza vaccines may be co-administered with or given at any time before or after other vaccines (including live, inactivated, adjuvanted, or unadjuvanted vaccines), tuberculin skin tests or IGRA (QFT) tests.		
Additional Preparation Instructions	Shake product well before administration.		
Appearance	Clear to slightly opalescent suspension.	Opalescent translucent to off-white suspension that may sediment slightly.	Clear to slightly opalescent suspension.
Storage	- Store at +2°C to +8°C - Do not freeze. - Store in original packaging to protect from light. - Discard 28 days after first puncture into the vial for the multi-dose product. - Do not use beyond the labeled expiry date.		
Vaccine Code	FLU		
Antigen Code	FLU		
Licensed for	Individuals 6 months of age and older.		
Notes	1992 (approx.): Influenza vaccine split virus Influenza split virus vaccine first used in Canada in approximately 1992. (Fluviral & Vaxigrip) 2009 October: Influenza vaccine for H1N1 Pandemic universal program for everyone six months of age and older. 2009-October: Influenza seasonal vaccine universal program to include all Albertans six months of age and older. 2015 August 12: Influenza Vaccines 2015-2016 season: Fluad (all Albertans aged 65 years and older), Flumist Quadrivalent, Fluviral, Influvac (This is the vaccine of choice for adults 18 to 64 years of age). 2016 August 29: Influenza vaccines 2016-2017 season: Fluzone, Fluad, Flumist 2017 July: Influenza Vaccines 2017-2018 season: Fluzone, Fluad. 2018 August: Influenza Vaccines 2018-2019 season: Fluzone, FluLaval Tetra. 2019: Influenza Vaccine 2019-2020 season: Fluzone, FluLaval Tetra. 2020: Influenza Vaccines 2020-2021 season: Fluzone, FluLaval Tetra, Alfuria Tetra, Trivalent Fluzone HD (65 years of age and older who reside in long term care beds). 2021: Influenza Vaccine 2021-2022 season: Fluzone, FluLaval Tetra, Alfuria Tetra, Fluzone HD (65 years of age and older). 2022: Influenza Vaccine 2022-2023 season: Fluzone, FluLaval Tetra, Alfuria Tetra, Fluzone HD (65 years of age and older). 2023: Influenza Vaccines 2023-2024 season: Fluzone, FluLaval Tetra, Fluzone HD (65 years of age and older). 2024: Influenza Vaccines 2024-2025 season: Flucelvax, Fluzone, FluLaval Tetra, Fluzone HD (65 years of age and older). 2025: Influenza Vaccines 2025-2026 season: Fluzone, Flucelvax, Fluviral, Fluad (65 years of age and older), Fluzone HD (HSCT, SOT and CAR-T cell, 18 years of age and older). 2026: Influenza Vaccines 2026-2027 season: Fluzone, Flucelvax, Fluviral, Fluad (65 years of age and older), Fluzone HD (HSCT, SOT and CAR-T cell, 18 years of age and older)		
Related Resources	Primary Care Alberta Website (2026). Influenza Immunization Influenza (flu) Primary Care Alberta Website (2026). Influenza Immunization: Information for Health Professionals Influenza Immunization Information for Health Professionals		

	FLUCELVAX	Fluviral	Fluzone
References Alberta HSCT program physicians. Expert opinion. (November 2023 and September 2024). In <i>Alberta Immunization Policy: Standard Dose Influenza Vaccines Trivalent Inactivated</i>. Government of Alberta. GlaxoSmithKline Inc. (May 1, 2026) FLUVIRAL (2026-2027) Trivalent Influenza Vaccine (Split Virion, Inactivated). Health Canada drug product database. https://pdf.hres.ca/dpd_pm/00085961.PDF Kwong, J. C., Vasa, P. P., Campitelli, S. H., et al. (2013). Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounter: a self-controlled study. <i>Lancet Infectious Disease</i>, 13, 769-76. National Advisory Committee on Immunization (2026, May 12). <i>Statement on seasonal influenza vaccine for 2026-2027</i>. Public Health Agency of Canada. Primary and Preventative Health Services. (2026, October 1) Standard Dose Influenza Vaccines Trivalent Inactivated. In <i>Alberta immunization Policy: Biological Products</i>. (2025). Government of Alberta. Public Health Agency of Canada. (2024, September 3). <i>Canadian Immunization Guide</i>. Government of Canada. Sanofi Pasteur Inc. (May 29, 2026). FLUZONE Influenza Virus Vaccine Trivalent Types A and B (Split Virion). Health Canada drug product database. https://pdf.hres.ca/dpd_pm/00085964.PDF Seqirus Canada Inc. (May 13, 2026) FLUCELVAX (2026-2027) Influenza Vaccine (surface antigen, inactivated, prepared in cell cultures). Health Canada drug product database. https://pdf.hres.ca/dpd_pm/00084522.PDF World Health Organization. https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2026-2027-northern-hemisphere-influenza-season			